DXSE:F:F-Xtrackers Stoxx Europe 600 Health Care Swap UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 236.05

Change

-2.95 (-1.23)%

Market Cap

USD 0.16B

Volume

26.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.03 (-0.09%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.05 (+0.10%)

USD 115.53B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 96.59B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+0.60 (+0.25%)

USD 57.94B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 54.05B
VUSA:F Vanguard Funds Public Limited ..

+0.24 (+0.24%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.28 (+0.28%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 40.74B
0ZC:F Zscaler Inc

-3.78 (-2.48%)

USD 37.92B

ETFs Containing DXSE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.46% 82% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.46% 80% B- 67% D+
Trailing 12 Months  
Capital Gain 17.76% 73% C 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.76% 70% C- 64% D
Trailing 5 Years  
Capital Gain 64.91% 82% B 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.91% 82% B 64% D
Average Annual (5 Year Horizon)  
Capital Gain 8.51% 73% C 70% C-
Dividend Return 8.51% 72% C 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.20% 70% C- 89% A-
Risk Adjusted Return 103.78% 99% N/A 97% N/A
Market Capitalization 0.16B 36% F 36% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.